Psychiatr. pro Praxi, 2003; 1: 6-9

Některé možnosti kombinace psychofarmak v klinické praxi

prof. MUDr. Eva Češková CSc, MUDr. Tomáš Kašpárek Ph.D
Psychiatrická klinika LF MU a FN Brno

Keywords: depressive disorder, schizophrenic disorder, pharmacoresistance, combination of antidepressants, combination of antipsychotics.

Published: December 31, 2003  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Češková E, Kašpárek T. Některé možnosti kombinace psychofarmak v klinické praxi. Psychiatr. praxi. 2003;4(1):6-9.

Autoři popisují důvody, historii a současný výskyt kombinací antidepresiv u depresivní poruchy a kombinací antipsychotik u schizofrenní poruchy. S dostupnou literaturou konfrontují vlastní údaje o užití kombinací v brněnském regionu. Dále uvádí konkrétní možnosti a shrnují jejich výhody či nevýhody. Perspektivní se jeví kombinace látek s rozdílným (resp. komplementárním) farmakologickým profilem. Přes častou aplikaci kombinací je studií, které by prokazovaly větší účinnost kombinací nad monoterapií, překvapivě málo. Pokud tuto léčebnou strategii použijeme, měli bychom zvažovat teoretické zdůvodnění i možná rizika. Častý výskyt kombinací lze vysvětlit vývojem nových, specifičtějších a bezpečnějších psychofarmak, realitou klinické praxe a v neposlední řadě důvody ekonomickými. Vzhledem k této skutečnosti se jeví nezbytné realizovat kontrolované studie s větším počtem léčených, které by vedly ke zhodnocení jejich účinnosti.

POSSIBILITIES OF COMBINATION OF PSYCHOTHERAPEUTICS IN CLINICAL PRACTICE

The authors describe reasons, history and occurrence of both antidepressants and antipsychotics combinations in depressive and schizophrenic disorders. Own results with their use in Brno region are compared with the literature. Further concrete possibilities are presented and their advantages and disadvantages are summarised. The most promising seem to be combinations of drugs with different (respective complementary) pharmacological profiles. In spite of frequent use of combinations the studies concerning the efficacy of this strategy are scare. Using combinations, the theoretical reasons and possible risks should be considered. The polypharmacy may be explained by the availability of new more specific and safer psychopharmacs, reality of clinical praxis and last but not least by economic reasons. In the near future more controlled studies with greater number of treated should be performed, aimed at the evaluation of combination efficacy.

Download citation

References

  1. Appeelberg BG, Syvalahti EK, Koskinen TE, et al. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo controlled, randomized, double-blind, placebo wash-in study. J Clin Psychiatry 2001; 62: 448-452. Go to original source... Go to PubMed...
  2. Bacher NM, Kaup BA. Combining risperidone with standard neuroleptics for refractory schizophrenic patientes (letter). Am J Psychiatry 1996; 153: 137. Go to original source... Go to PubMed...
  3. Bhatara VS, Magnus RD, Paul KL, Preskorn SH. Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms. Ann Pharmacother 1998; 32: 432-436. Go to original source... Go to PubMed...
  4. Bodkin JA, Lasser RA, Wines JD Jr, et al. Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry 1997; 58: 137-145. Go to original source... Go to PubMed...
  5. Canales PL, Olsen J, Miller AL, et al. Role of antipsychotic polypharmacotherapy in the treatment of schizophrenia. CNS Drugs 1999; 12: 179-88. Go to original source...
  6. Carpenter LL, Yasmin S, Price LH. A double blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry 2002; 51: 183-188. Go to original source... Go to PubMed...
  7. Carta MG, Hardoy MC, Harody MJ. Amisulpride and fluvoxamine: early onset of SSRI action in major depression. Int J Neuropsychopharmacol (Abstracts of XXIInd C.I.N.P. Congress, Brussels, Belgium) 2000; 3: suppl. 1, 224.
  8. Češková E, Kašpárek T, Ondrušová M. Kombinace antipsychotik. Č.-S. Psychiatrie 2001; 97: 286-290.
  9. Češková E, Kašpárek T. Polyfarmakoterapie u depresivní poruchy. Č.-S. Psychiatrie 2002; 98: 128-134.
  10. Chue P, Welch R, Snaterse M. Combination risperidone and quetiapine therapy in refractory schizophrenia. Can J Psychiatry 2001; 46: 86-87.
  11. Clark RE, Bartels SJ, Mallman TA, Peacock WJ. Recent trend in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental healthy policy. Schizophrenia Bull 2002; 28: 75-84. Go to original source... Go to PubMed...
  12. Clayton AH, McGarvey EL, Warnock J, Kornstein S. Bupropion SR as an antidot to SSRI-induced sexual dysfunction. Presented at the 40th Annual N.C.D.E.U. Meeting, Boca Raton, Florida 2000.
  13. Davidson J, McLeod M, Law-Yone B, et al. A comparison of electroconvulsive therapy and combined phenelzine-amitriptyline in refractory depression. Arch Gen Psychiatry 1978; 35: 639-642. Go to original source... Go to PubMed...
  14. Debonnel G, Gobbi G, Turcotte J, et al. Effects of mirtazapine, paroxetine and their combination. A double-blind study in major depression. Abstracts of XVth E.C.N.P. Congress, 2000; 252. Go to original source...
  15. Dube S, Anderson SW, Corya SA, et al. Olanzapine-fluoxetine for treatment-resistant depression. Abstracts of XIIth World Congress of Psychiatry, August 24-29 Yokohama, Japan 2002; 239. Go to original source...
  16. Fava M, Rosenbaum J, McGrath PJ. et al. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression. Am J Psychiatry 1994; 15: 1372-1374. Go to original source...
  17. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996; 19: 179-200. Go to original source... Go to PubMed...
  18. Ferreri M, Lavergne F, Berlin I, et al. Benefits from mianserin augmentation of fluoxetine in patientes with major depression non-responders to fluoxetine alone. Acta Psychiatr Scand, 2001; 103: 66-72. Go to original source... Go to PubMed...
  19. Friedman J, Ault K, Powchik P. Pimozide augmentation for the treatment of schizophrenic patientes who are partial responders to clozapine. Biol Psychiatry 1997; 42: 522-523. Go to original source... Go to PubMed...
  20. Godleski LS, Kerler R, Barber JW, et al. Multiple versus single antipsychotic drug treatment in chronic psychosis. J Nerv Ment Dis 1989; 177: 686-689. Go to original source... Go to PubMed...
  21. Huttunen MO, Tuhkanen H, Haavisto E, et al. Low - and standard-dose depot haloperidol combined with targeted oral neuroleptics. Psychiatr Serv 1996; 47: 395-397. Go to original source...
  22. Joffe RT, Bakish D. Combined SSRI-moclobemide treatment of psychiatric illness. J Clin Psychiatry 1994; 55: 24-25.
  23. Joffe RT, Singer WA, Levitt AJ, MacDonald C. A placebo controlled comparison of lithium and trioodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 1993; 50: 87-393. Go to original source... Go to PubMed...
  24. Kissling W. Ideal and reality of neuroleptic relapse prevention. Br J Psychiatry 1992; 161: suppl., 133-139. Go to original source...
  25. Knight RG, Harrison A. A double-blind comparison of thiothixene and a trifluoperazine/chlorpromazine composite in the treatment of chronic schizophrenia. A Z Med J 1979; 89: 302-304.
  26. Lam RW, Wan DD, Cohen NL, Kennedy SH. Combining antidepressants for treatment-resistant depression: a review. J Clin Psychiatry 2002; 63: 685-693. Go to original source... Go to PubMed...
  27. Lerner V, Chudakova B, Kracvets S, Polyakova I. Combined use of risperidone and olanzapine in the treatment of patientes with resistant schizophrenia. A preliminary case series reports. Clin Neuropharmacology 23, 2000; 23: 284-286. Go to original source... Go to PubMed...
  28. Lucca A, Serretti A, Smeraldi E. Effect of reboxetine augmentation in SSRI resistant patientes. Hum Psychopharmacol Clin Exp 2000; 15: 143-145. Go to original source...
  29. Maes M, Librecht I, van Hunsel F, et al. Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patientes even in those with treatment resistance. Presented at XXIst C.I.N.P. Congress, Glasgow, 1998. Go to original source...
  30. Medhus A, Heskestad S, Tjemsland L. Mianserin added to tricyclic antidepressants in depressed patientes not responding to a tricyclic antidepressant alone: a randomized, placebo-controlled, double-blind study. Nord J Psychiatry 1994; 48: 355-358. Go to original source...
  31. Nelson JC, Mazure CM, Bowers MB, Jatlow P. A preliminary open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 1991; 48: 303-307. Go to original source... Go to PubMed...
  32. Preskorn SH, Beber JH, Faul JC, et al. Serious adverse effects of combining fluoxetine and tricyclic antidepressants. Letter. Am J Psychaitry 1990; 147: 532. Go to original source...
  33. Raskin S, Katz G, Zislin Z, et al. Clozapine and risperidone: combination/ augmentation treatment of refractory schizophrenia: a preliminary observation. Acta Psychiatr Scand 2000; 101: 334-336. Go to original source... Go to PubMed...
  34. Reinstein MJ, Sirotovskaya LA, Jones LE, Mohan S, Chasanov MA. Effect of clozapine-quetiapine combination therapy on weight and glycaemic control. Clinical Drug Investigation 1999; 18: 99-104. Go to original source...
  35. Shelton RC, Tollefson GD, Tohen, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001; 158: 131-134. Go to original source... Go to PubMed...
  36. Siloh R, Zemishlany D, Aizenberg D, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. Br J Psychiatry 1997; 171: 569-573. Go to original source... Go to PubMed...
  37. Stubbs JH, Haw CM, Staley CJ, Mountjoy CQ. Augmentation with sulpiride for a schizophrenic patients partially responsive to clozapine. Acta Psychiatr Scand 2000; 102: 390-393. Go to original source... Go to PubMed...
  38. Takhar J. Pimozide augmentation in a patient with drug-resistant psychosis previously treated with olanzapine (letter). J Psychiatr Neurosci 1999; 24: 248-249.
  39. Waring EW, Devin PG, Dewan V. Treatment of schizophrenia with antipsychotics in combination (letter). Can J Psychiatry 1999; 44: 189-190.
  40. Young JPR, Lader MH, Hughes WC. Controlled trial of trimipramine, monoamine oxidase inhibitors, and combined treatment in depressed outpatientes. Br Med J 1979; 2: 1313-1317. Go to original source... Go to PubMed...




Psychiatry for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.